BR9607538A - Lactobacilos aderentes ao epitélio - Google Patents

Lactobacilos aderentes ao epitélio

Info

Publication number
BR9607538A
BR9607538A BR9607538A BR9607538A BR9607538A BR 9607538 A BR9607538 A BR 9607538A BR 9607538 A BR9607538 A BR 9607538A BR 9607538 A BR9607538 A BR 9607538A BR 9607538 A BR9607538 A BR 9607538A
Authority
BR
Brazil
Prior art keywords
pct
mannose
date sep
sec
strain
Prior art date
Application number
BR9607538A
Other languages
English (en)
Inventor
Ingegerd Adlerberth
Siv Ahrne
Bengt Jeppsson
Marie-Louise Johansson
Goran Molin
Agnes Wold
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of BR9607538A publication Critical patent/BR9607538A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR9607538A 1995-03-23 1996-03-25 Lactobacilos aderentes ao epitélio BR9607538A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli
PCT/SE1996/000372 WO1996029083A1 (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli

Publications (1)

Publication Number Publication Date
BR9607538A true BR9607538A (pt) 1998-01-06

Family

ID=20397666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607538A BR9607538A (pt) 1995-03-23 1996-03-25 Lactobacilos aderentes ao epitélio

Country Status (16)

Country Link
US (1) US6159465A (pt)
EP (1) EP0817640B1 (pt)
JP (1) JP4072646B2 (pt)
KR (1) KR100446482B1 (pt)
CN (1) CN1138551C (pt)
AT (1) ATE240738T1 (pt)
AU (1) AU702705B2 (pt)
BR (1) BR9607538A (pt)
CA (1) CA2216150C (pt)
DE (1) DE69628288T2 (pt)
EE (1) EE04097B1 (pt)
ES (1) ES2200057T3 (pt)
NO (1) NO974371L (pt)
PL (1) PL184037B1 (pt)
SE (1) SE9501056D0 (pt)
WO (1) WO1996029083A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376954B1 (ko) * 1995-07-31 2003-07-18 프로비 에이비 장에서집락화하는유산간균
JP2002507997A (ja) * 1997-07-05 2002-03-12 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 腸管細胞によるミネラルの吸収
FI974643L (fi) * 1997-12-30 1999-07-01 Atria Oyj Biologinen menetelmä salmonellan eliminoimiseksi prosesseista ja rakenteista
US6830750B1 (en) * 1998-10-01 2004-12-14 Probi Ab Reduction of oxidative stress factors with Lactobacillus plantarum
CA2378620A1 (en) * 1999-08-09 2001-02-15 Pinaki Panigrahi Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
AP1563A (en) 1999-10-26 2006-02-02 Nestle Sa Lactic acid bacteria for the treatment and /or prophylaxis of giardiasis.
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
CA2450444A1 (fr) * 2001-06-14 2002-12-27 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes
FR2831555A1 (fr) * 2001-10-29 2003-05-02 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
FR2826020B1 (fr) * 2001-06-14 2005-02-11 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
EP1730179B1 (en) * 2004-03-23 2010-04-28 Friesland Brands B.V. Novel mannose-specific adhesins and their use
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
JP2006180836A (ja) * 2004-12-28 2006-07-13 Marudai Food Co Ltd 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物
JP2006257077A (ja) * 2005-02-18 2006-09-28 Marudai Food Co Ltd 免疫調節剤および免疫調節食品
CN1888051B (zh) * 2005-06-28 2010-05-05 北京天佑达生物工程科技有限公司 一株植物乳杆菌及其应用
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
EP1931363B1 (en) 2005-09-28 2015-11-18 Nordisk Rebalance A/S Treatment of ibd using both probiotic bacteria and fermented cereal as treatment effectors
KR101397386B1 (ko) 2005-12-13 2014-05-26 엑스테라 메디컬 코퍼레이션 혈액으로부터 병원성 미생물, 염증 세포 또는 염증단백질의 체외 제거를 위한 방법
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
FR2928935B1 (fr) 2008-03-19 2011-05-20 Gervais Danone Sa Souche de lactobacillus rhamnosus.
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
ES2861359T3 (es) 2009-12-01 2021-10-06 Exthera Medical Corp Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie
CN102905712B (zh) 2010-01-28 2015-12-16 Ab－生物学有限公司 用于治疗肠炎的益生菌组合物
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
BG66608B1 (bg) * 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
CN102618456B (zh) * 2012-02-28 2013-08-21 江南大学 一种能够缓解慢性酒精性肝损伤的鼠李糖乳杆菌及其用途
EP2861273B1 (en) 2012-06-13 2017-08-23 ExThera Medical Corporation Use of heparin and carbohydrates to treat cancer
JP2012184261A (ja) * 2012-06-21 2012-09-27 Snow Brand Milk Products Co Ltd 免疫増強剤
CN102827796B (zh) * 2012-09-03 2013-10-30 江南大学 一种具有排镉功能的植物乳杆菌及其用途
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
BR112015032134B1 (pt) 2013-06-24 2022-05-10 Exthera Medical Corporation Método de ligação em ponto de extremidade de uma manose não redutora a um substrato e esfera possuindo uma manose ligada em ponto de extremidade
BR112016009827B1 (pt) 2013-11-08 2021-10-26 Exthera Medical Corporation Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit
EP3134146B1 (en) 2014-04-24 2024-12-25 ExThera Medical Corporation Method for removing bacteria from blood using high flow rate
US10857283B2 (en) 2014-09-22 2020-12-08 Exthera Medical Corporation Wearable hemoperfusion device
CN108235682A (zh) 2015-09-29 2018-06-29 金伯利-克拉克环球有限公司 用于维护微生物群落的健康平衡的协同组合物
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
KR102769558B1 (ko) 2017-02-28 2025-02-19 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물
KR102024883B1 (ko) 2017-11-24 2019-09-24 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
MY202164A (en) 2018-05-09 2024-04-09 Kobiolabs Inc Lactobacillus paracasei strain and use thereof
KR102138834B1 (ko) 2018-05-23 2020-07-29 주식회사 고바이오랩 락토바실러스 가세리 kbl697 균주 및 그 용도
WO2020231830A1 (en) 2019-05-16 2020-11-19 Exthera Medical Corporation Method for modulating endothelial glycocalyx structure
MY199150A (en) 2019-06-05 2023-10-18 Morinaga Milk Industry Co Ltd Nutritional composition
CN111575223B (zh) * 2020-05-20 2022-04-15 江南大学 一种降低鼠李糖乳杆菌表面物质分泌量的方法
CN119242500A (zh) * 2024-09-30 2025-01-03 尚品健康科技(青岛)有限公司 一株母乳来源植物乳植杆菌改善过敏性疾病和调节肠道菌群的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203586A3 (en) * 1985-05-29 1988-03-09 Pioneer Hi-Bred International A composition for treating gastrointestinal disease in animals
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB9124249D0 (en) * 1991-11-14 1992-01-08 Goldstein Fredric Ribbon curling and shredding device
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection

Also Published As

Publication number Publication date
SE9501056D0 (sv) 1995-03-23
CA2216150A1 (en) 1996-09-26
EE04097B1 (et) 2003-08-15
WO1996029083A1 (en) 1996-09-26
NO974371L (no) 1997-11-20
PL322550A1 (en) 1998-02-02
ATE240738T1 (de) 2003-06-15
EE9700329A (et) 1998-06-15
CA2216150C (en) 2008-01-22
NO974371D0 (no) 1997-09-22
EP0817640B1 (en) 2003-05-21
PL184037B1 (pl) 2002-08-30
CN1185111A (zh) 1998-06-17
KR100446482B1 (ko) 2006-01-27
CN1138551C (zh) 2004-02-18
EP0817640A1 (en) 1998-01-14
AU702705B2 (en) 1999-03-04
AU5166596A (en) 1996-10-08
ES2200057T3 (es) 2004-03-01
DE69628288T2 (de) 2004-04-08
DE69628288D1 (de) 2003-06-26
JPH11502703A (ja) 1999-03-09
HK1017989A1 (en) 1999-12-10
KR19980703102A (ko) 1998-10-15
JP4072646B2 (ja) 2008-04-09
US6159465A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
BR9607538A (pt) Lactobacilos aderentes ao epitélio
Blum et al. Adhesion studies for probiotics: need for validation and refinement
Chauvière et al. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells
Coconnier et al. Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain LB decreases bacterial invasion
Jensen et al. In vitro testing of commercial and potential probiotic lactic acid bacteria
Gopal et al. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli
Mayrand et al. Biological activities of outer membrane vesicles
Coconnier et al. Protein-mediated adhesion of Lactobacillus acidophilus BG2FO4 on human enterocyte and mucus-secreting cell lines in culture
Lamont et al. Subgingival colonization by Porphyromonas gingivalis
Reid Probiotic agents to protect the urogenital tract against infection
TR200101699T2 (tr) Urogenital enfeksiyonların önlenmesi ve tedavisi için ağızdan lactobakilus uygulaması
AU2613995A (en) Lactobacillus strains of human origin, their compositions and uses thereof
Li et al. Association of proteases of Porphyromonas (Bacteroides) gingivalis with its adhesion to Actinomyces viscosus
AU6040001A (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
Neilands et al. Parvimonas micra stimulates expression of gingipains from Porphyromonas gingivalis in multi-species communities
WO2002083879A3 (en) Immunotherapy based on dendritic cells
GR3027620T3 (en) Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
Melgar-Lalanne et al. In vitro evaluation of the probiotic potential of halotolerant lactobacilli isolated from a ripened tropical Mexican cheese
EE03597B1 (et) Farmatseutiline kompositsioon, mis sisaldab Lactobacillus plantarum'it ja arginiini
WO2003039260A3 (en) PROBIOTIC COMPOSITIONS
Henriksson et al. Adhesion of Lactobacillus fermentum 104-S to porcine stomach mucus
Aleljung et al. Collagen binding by lactobacilli
Viboud et al. Binding of enterotoxigenicEscherichia coliexpressing different colonization factors to tissue-cultured Caco-2 cells and to isolated human enterocytes
Akesson et al. Targeting of streptococci by zoocin A
DK0858501T3 (da) Mælkesyrebakteriepræparater samt deres anvendelse til fremstilling af kolesterolsænkende produkter

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal